Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

August 14, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

June 11, 2018

Conditions
Liver Transplant RecipientsLiver TransplantationImmunosuppression
Interventions
DRUG

Immunosuppression withdrawal

Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.

Trial Locations (12)

10032

New York Presbyterian Morgan Stanley Children's Hospital - Columbia University Medical Center, New York

15224

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

30322

Emory University and Children's Hospital of Atlanta, Atlanta

45229

Cincinnati Children's Hospital, Cincinnati

60614

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

St. Louis Children's Hospital - Washington University, St Louis

77030

Texas Children's Hospital, Houston

80045

Children's Hospital of Colorado, Aurora

94143

University of Michigan C. S. Mott Children's Hospital, Ann Arbor

94143-0780

University of California, San Francisco

M5G1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01638559 - Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients | Biotech Hunter | Biotech Hunter